<DOC>
	<DOCNO>NCT00390832</DOCNO>
	<brief_summary>The purpose study determine whether erythropoietin superior placebo respect leave ventricular ejection fraction patient ST-elevation myocardial infarction undergo percutaneous coronary intervention .</brief_summary>
	<brief_title>Efficacy Study Erythropoietin After Revascularization Myocardial Infarction ( REVIVAL-3 )</brief_title>
	<detailed_description>Erythropoietin lately show exert others merely hematopoietic function . Due attenuation cell apoptosis necrosis and/or enhance neovascularisation , erythropoietin could protective myocardial ischemia reperfusion lead infarct size reduction improvement leave ventricular function . In controlled clinical trial , short-term administration erythropoietin patient ischemic stroke associate significantly well functional recovery , low level circulate damage marker strong trend small infarct size measure magnetic resonance imaging . While leave hematocrit platelet count unchanged , short-term administration erythropoietin show safe well tolerate ( side effect report observed ) . The protective effect short-term erythropoietin acute ischemic brain damage evaluate ongoing multi-center trial Germany . Considering preclinical clinical data erythropoietin attractive candidate evaluate patient acute myocardial infarction . In pilot trial enrol 22 patient acute myocardial infarction short-term administration erythropoietin show safe significantly increase level endothelial progenitor cell percutaneous coronary intervention . However , small population allow evaluate benefit leave ventricular function clinical outcome . The aim REVIVAL-3 study investigate whether additional benefit short-term administration erythropoietin patient acute myocardial infarction successful primary percutaneous coronary intervention ( PCI ) term leave ventricular ejection fraction .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Patients STSegment elevation myocardial infarction &lt; 24 h pain onset Successful primary PCI leave ventricular ejection fraction &lt; 50 % Informed , write consent In woman childbearing potential pregnancy test mandatory Age &lt; 18 &gt; 80 year Cardiogenic shock pericarditis thrombolysis index infarction malignancies/other comorbid condition life expectancy &lt; 1 year previous myocardial infarction plan stag PCI prior PCI within 30 day index procedure uncontrolled hypertension &gt; 160/100mmHg unresponsive therapy epilepsy active bleeding ; bleed diathesis ; history gastrointestinal genitourinary bleeding , recent trauma major surgery &lt; 1 month ; history intracranial bleed structural abnormality ; suspect aortic dissection ; patient 's refusal blood transfusion hematologic disorder essential thrombocytosis , megakaryoblastic leukemia , polycythemia vera relevant hematologic deviation : hemoglobin &lt; 100 g/l hemoglobin &gt; 160 g/l platelet count &lt; 100 x 10^9 cells/l platelet count &gt; 600 x 10^9 cells/l contraindication magnetic resonance imaging : electronically , magnetically mechanically activated implant cardiac pacemaker , automatic cardioverter defibrillator , joint prosthesis , surgical/vascular clips/ hearing aid , neurostimulators , infusion pump etc metallic splinter eye ferromagnetic haemostatic clip central nervous system cochlear implant lead wire similar wire prosthetic heart valve , dehiscence suspect nonferromagnetic stapedial implant , hemostatic clip glomerular filtration rate &lt; 30 ml/min serum creatinine &gt; 30 mg/l dependence renal dialysis chronic liver disease GOT &gt; 5fold normal range allergy erythropoietin/true anaphylaxis prior exposure contrast medium phenylketonuria previous enrollment trial woman know pregnant , childbearing potential test positive pregnancy , give birth within last 90 day , breastfeed patient 's inability fully cooperate study protocol contraindication accord summary product characteristic recombinant human erythropoietin beta ( NeoRecormonÂ® )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2009</verification_date>
	<keyword>STEMI</keyword>
</DOC>